Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PLS240

Phase 3Small molecule

PPathalys Pharma

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney Disease (CKD)Not yet recruiting

Chronic Kidney Disease (CKD)Phase 3

Not yet recruiting

Timeline

Expected Milestones

Q1 2032

Phase 3Not yet recruiting

Chronic Kidney Disease (CKD)

NCT07890584

Clinical

Trials by Indication[1]

Hemodialysis2 trials

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

Completed·PPathalys Pharma·Phase 3·NCT05832931·362 enrolled

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

Completed·PPathalys Pharma·Phase 3·NCT05836220·412 enrolled

Chronic Kidney Disease (CKD)1 trial

A Randomized, Open-label, Controlled, Multiple Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of PLS240 in Pediatric Participants 1 Month to <18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

Not yet recruiting·PPathalys Pharma·Phase 3·NCT07890584·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PLS240. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PLS240 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PLS240. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pathalys Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPathalys Pharma

Related News